Publication:
Seguridad y efectividad del oxihidroxido sucroferrico en pacientes españoles en diálisis: subanalisis del estudio VERIFIE

Loading...
Thumbnail Image

Date

2021-04-18

Authors

Auxiliadora Bajo, Maria
Rios Moreno, Francisco
Dolores Arenas, Maria
Deuesa Such, Ramon Jesus
Molina Higueras, Maria Jose
Delgado, Margarita
Molina, Pablo
Garcia Fernandez, Nuria
Martin Malo, Alejandro
Peiro-Jordan, Roser

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Soc espanola nefrologia dr rafael matesanz
Elsevier
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Background and aims: In this study, we show the results of the subset of Spanish patients of the VERIFIE study, the first post-marketing study assessing the long-term safety and effectiveness of sucroferric oxyhydroxide (SFOH) in patients with hyperphosphatemia undergoing dialysis during clinical practice. Patients and methods: Patients undergoing hemodialysis and peritoneal dialysis with indication of SFOH treatment were included. Follow-up duration was 12–36 months after SFOH initiation. Primary safety variables were the incidence of adverse drug reactions (ADRs), medical events of special interest (MESIs), and variations in iron-related parameters. SFOH effectiveness was evaluated by the change in serum phosphorus levels. Results: A total of 286 patients were recruited and data from 282 were analyzed. Among those 282 patients, 161 (57.1%) withdrew the study prematurely and 52.5% received concomitant treatment with other phosphate binders. ADRs were observed in 35.1% of patients, the most common of which were gastrointestinal disorders (77.1%) and mild/moderate in severity (83.7%). MESIs were reported in 14.2% of patients, and 93.7% were mild/moderate. An increase in ferritin (386.66ng/mL vs 447.55ng/mL; p = 0.0013) and transferrin saturation (28.07% vs 30.34%; p = 0.043) was observed from baseline to the last visit (p = 0.0013). Serum phosphorus levels progressively decreased from 5.69mg/dL at baseline to 4.84mg/dL at the last visit (p < 0.0001), increasing by 32.2% the proportion of patients who achieved serum phosphorus levels ≤5.5mg/dL, with a mean daily SFOH dose of 1.98 pills/day. Conclusions: SFOH showed a favorable effectiveness profile, a similar safety profile to that observed in the international study with most adverse events of mild/moderate severity, and a low daily pill burden in Spanish patients in dialysis.

Description

MeSH Terms

Drug Combinations
Ferric Compounds
Humans
Phosphorus
Renal Dialysis

DeCS Terms

CIE Terms

Keywords

Dialysis, Sucroferric oxyhydroxide, Phosphate binder, Safety, Clinical practice, Chronic kidney-disease, Phosphate binder pa21, Hemodialysis-patients, Hyperphosphatemia, Efficacy, Bone, Dialisis, Oxihidroxido sucroferrico, Captor de fosforo, Seguridad, Practica clinica

Citation

Bajo MA, Ríos-Moreno F, Arenas MD, Devesa-Such RJ, Molina-Higueras MJ, Delgado M, et al. Safety and effectiveness of sucroferric oxyhydroxide in Spanish patients on dialysis: sub-analysis of the VERIFIE study. Nefrologia (Engl Ed). 2022 Sep-Oct;42(5):594-606